<DOC>
	<DOCNO>NCT01755494</DOCNO>
	<brief_summary>The primary objective study assess pharmacokinetic parameter saxagliptin metformin healthy male Chinese subject .</brief_summary>
	<brief_title>A Bioequivalence Study Fixed Dose Combinations Saxagliptin/Metformin XR Relative Co-Administration</brief_title>
	<detailed_description>A Single-centre , Randomized , Open-label , Two-period , Cross-over , Bioequivalence Study Fixed Dose Combinations Saxagliptin/Metformin XR Relative Co-Administration Individual Components two cohort Healthy Chinese Subjects Fed Conditions</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Chinese ethnicity define parent 4 grandparent Chinese Healthy male subject determine clinically significant deviation normal medical history , physical examination , ECGs , clinical laboratory determination Men , age 18 40 year , inclusive . The age difference among subject within 10 year Weigh least 50 kg body mass index ( BMI ) 19 24 kg/m2 Sexually active fertile men must use effective birth control throughout study 90 day last dose investigational product partner woman child bear potential Any significant acute chronic medical illness Current recent gastrointestinal disease Subjects lymphocytopenia thrombocytopenia History autoimmune skin disorder Estimatedcreatinine clearance le 80 mL/min</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Type 2 diabetes , Saxagliptin , Metformin , Fixed dose combination tablet , Bioequivalence , pharmacokinetic , safety , tolerability</keyword>
</DOC>